Population pharmacokinetics of telavancin in healthy subjects and patients with infections

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 4, 2012, Pages 2067-2073

  Samara, Emil ^a   Shaw, Jeng Pyng ^b,c   Barriere, Steven L ^b   Wong, Shekman L ^b,d   Worboys, Philip ^b  

^a PharmaPolaris International Inc   (United States)

^b THERAVANCE INC   (United States)

^c BioDuro   (China)

^d ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TELAVANCIN;

ADULT; AGED; ARTICLE; BODY WEIGHT; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REGIMEN; ERADICATION THERAPY; FEMALE; GENDER; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN AND SKIN STRUCTURE INFECTION; SKIN INFECTION;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BACTERIAL INFECTIONS; BAYES THEOREM; BODY WEIGHT; CALIBRATION; CROSS INFECTION; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; POPULATION; SEX CHARACTERISTICS; YOUNG ADULT;

EID: 84858685935     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05915-11     Document Type: Article

References (25)

1. Astellas Pharma US, Inc. 2009. Vibativ package insert. Astellas Pharma US, Inc, Deerfield, IL.
2. Barriere S, et al. 2004. Effects of a new antibacterial, telavancin, on cardiac repolarization (QTc interval duration) in healthy subjects. J. Clin. Pharmacol. 44:689-695. (Pubitemid 38765930)
3. Battistini N, et al. 1995. Relative expansion of extracellular water in obese vs. normal children. J. Appl. Physiol. 79:94-96.
4. Beal SL, Sheiner LB. 1988-1998. NONMEM user's guides, parts I to VIII. NONMEM Project Group, University of California at San Francisco, San Francisco, CA.
5. Cockcroft DW, Gault MH. 1976. Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41.
6. Duchin K, et al. 2004. Single dose pharmacokinetics (PK) of telavancin (TLV) in subjects with renal dysfunction, abstr 1028. 14th Eur. Congr. Clin. Microbiol. Infect. Dis. Prague, Czech Republic, 1 to 4 May 2004.
7. Goldberg MR, Wong SL, Shaw JP, Kitt MM, Barriere SL. 2010. Lack of effect of moderate hepatic impairment on the pharmacokinetics of telavancin. Pharmacotherapy 30:35-42.
8. Goldberg MR, Wong SL, Shaw JP, Kitt MM, Barriere SL. 2010. Single-dose pharmacokinetics and tolerability of telavancin in elderly men and women. Pharmacotherapy 30:806-811.
9. Gotfried MH, et al. 2008. Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics. Antimicrob. Agents Chemother. 52:92-97.
10. Hegde SS, et al. 2004. Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against Gram-positive bacteria. Antimicrob. Agents Chemother. 48:3043-3050. (Pubitemid 38989173)
11. Higgins DL, et al. 2005. Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 49: 1127-1134. (Pubitemid 40327734)
12. Krause KM, et al. 2008. In vitro activity of telavancin against resistant Gram-positive bacteria. Antimicrob. Agents Chemother. 52:2647-2652. (Pubitemid 351915701)
13. Leadbetter MR, et al. 2004. Hydrophobic vancomycin derivatives with improved ADME properties: discovery of telavancin (TD-6424). J. Antibiot. (Tokyo) 57:326-336. (Pubitemid 38811717)
14. Lodise T, et al. 2010. Mouse thigh MRSA infection model data and mathematical modelling to determine telavancin dosing for complicated skin and skin structure infection trials, abstr P1602. 20th Eur. Congr. Clin. Microbiol. Infect. Dis., Vienna, Austria, 10 to 13 April 2010.
15. Lodise TP, Butterfield JM, Hegde SS, Samara E, Barriere SL. 2012. Telavancin pharmacokinetics and pharmacodynamics in patients with complicated skin and skin structure infections and various degrees of renal function. Antimicrob. Agents Chemother. 56:2062-2066.
16. Lunde CS, et al. 2009. Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II. Antimicrob. Agents Chemother. 53:3375-3383.
17. Rubinstein E, et al. 2011. Telavancin versus vancomycin for hospital-acquired pneumonia due to Gram-positive pathogens. Clin. Infect. Dis. 52:31-40.
18. Shaw JP, et al. 2005. Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects. Antimicrob. Agents Chemother. 49:195-201. (Pubitemid 40065793)
19. Stryjewski ME, et al. 2006. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study. Antimicrob. Agents Chemother. 50:862-867. (Pubitemid 43327787)
20. Stryjewski ME, et al. 2008. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by Grampositive organisms. Clin. Infect. Dis. 46:1683-1693. (Pubitemid 351706765)
21. Stryjewski ME, et al. 2005. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to Gram-positive bacteria. Clin. Infect. Dis. 40:1601-1607. (Pubitemid 40720810)
22. Sun HK, et al. 2006. Tissue penetration of telavancin after intravenous administration in healthy subjects. Antimicrob. Agents Chemother. 50: 788-790. (Pubitemid 43191003)
23. Waki M, et al. 1991. Relative expansion of extracellular fluid in obese vs. nonobese women. Am. J. Physiol. 261:E199-E203.
24. Wong SL, Barriere SL, Kitt MM, Goldberg MR. 2008. Multiple-dose pharmacokinetics of intravenous telavancin in healthy male and female subjects. J. Antimicrob. Chemother. 62:780-783.
25. Wong SL, Goldberg MR, Ballow CH, Kitt MM, Barriere SL. 2010. Effect of telavancin on the pharmacokinetics of the cytochrome P450 3A probe substrate midazolam: a randomized, double-blind, crossover study in healthy subjects. Pharmacotherapy 30:136-143.